ASX Release

25 May 2018

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 45
108 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contacts
Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Tickers:
Australia (ASX): ZLD
USA (OTC): ZLDAF

Ordinary Shares:
755,341,934

Options:
46,000,000

1,500,000 ($0.04 – 6/2/2020)
*4,500,000 ($0.04 – 6/2/2020)
40,000,000 ($0.03125 – 17/11/2021)
** subject to vesting conditions*

CHANGE OF REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS

Zelda Therapeutics Ltd (**ASX: ZLD, "Zelda"** or the **Company**) wishes to advise that with effect from 28 May 2018 the Company's address details will change to the following:

Registered Office & Principal Place of Business
Level 26
140 St Georges Terrace
Perth WA 6000

The following details remain the same:

Postal Address
PO Box 5457
PERTH WA 6831

Telephone: 08 6558 0886
Fax: 08 6316 3337

For further information please contact:

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com**)**

Zelda Therapeutics Ltd ("Zelda") is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A **human clinical trial programme** focused on insomnia, autism and eczema with activities in Australia, Chile and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

  It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.